FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4

Lana McClements(University of Technology Sydney), Tracy Robson(Queen's University Belfast)
BMC Cancer
April 11, 2019
Cited by 67


Related Papers

The Concise Guide to PHARMACOLOGY 2023/24: Enzymes
|British Journal of Pharmacology|2023|442
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
|British Journal of Pharmacology|2021|384